PLENARY SESSION I: STATE OF THE BIOTECHNOLOGY INDUSTRY ADDRESS

The state of the biotechnology address is a broad view of the industry from the perspectives of experts representing the industry's trade organization, a biotechnology company, and a financial institution.

Panel:

Scott Whitaker, COO, Biotechnology Industry Organization

Scott Whitaker joined BIO in February 2005 as the Chief Operating Officer, managing all aspects of BIO's day-to-day operations. Prior to joining BIO, Scott served as Chief of Staff at the Department of Health & Human Services. As Chief of Staff, Scott managed all the day-to-day operations of the Department and led the Department's activities on all major policy and management issues and initiatives. In addition, he served as the top liaison between the department and the White House on all policy, management and political matters. Prior to becoming Chief of Staff, Scott was nominated by the President and confirmed by the Senate to serve as Assistant Secretary for Legislation, Department of Health and Human Services. In that capacity, Scott led the legislative operations of the department and its agencies. During his time as Assistant Secretary, Scott managed the passage of a significant number of legislative victories for the Administration, including the Bioterrorism Preparedness Act of 2002, the Medical Device User Fee and Modernization Act of 2002, and the Project BioShield Act of 2004. Before joining HHS, Scott served on the staff of Senate Assistant Majority Leader Don Nickles (R-OK). He joined Sen. Nickles in 1991. In 1997, Nickles appointed Scott as policy advisor for the Office of the Assistant Majority Leader, where he served for the next four years. Scott holds a Master's degree from Johns Hopkins University and a Bachelor's degree from Palm Beach Atlantic University. He and his wife, Michelle, have two children.

Sam Saks, M.D., CEO, Jazz Pharmaceuticals, Inc.

Samuel Saks, M.D., joined Jazz Pharmaceuticals at its inception. From 2001 until he joined Jazz Pharmaceuticals, Dr. Saks was Company Group Chairman of ALZA Corporation and served as a member of the Johnson & Johnson Pharmaceutical Group Operating Committee. From 1992 until 2001, he held various positions with ALZA Corporation, most recently as its Chief Medical Officer and Group Vice President, where he was responsible for clinical and commercial activities. Dr. Saks received a B.S. and an M.D. from the University of Illinois. Dr. Saks serves on the board of Trubion Pharmaceuticals and Cougar Biotechnology.

Kleanthis Xanthopoulos, Ph.D., President and CEO of Regulus Therapeutics

Before joining Regulus, Dr. Xanthopoulos was a managing director of Enterprise Partners Venture Capital. Prior to that, he was a co-founder and served as President and Chief Executive Officer and Director of Anadys Pharmaceuticals from its inception in May 2000 to November 2006. From 1997 to 2000 he held a variety of positions at Aurora Biosciences Corporation (now Vertex Pharmaceuticals Incorporated) including Vice President, Genomics & Molecular Biology. Dr. Xanthopoulos participated in The National Institutes of Health (NIH) Human Genome Project and was a Section Head of the National Human Genome Research Institute at NIH from 1995 to 1997. He was an Associate Professor of Molecular Biology at the Karolinska Nobel Medical Institute, Stockholm, Sweden from 1991 to 1995, and a Postdoctoral Research Fellow at The Rockefeller University from 1987 to 1990. An Onassis scholar, Dr. Xanthopoulos received his B.Sc. in Biology with honors from Aristotle University of Thessaloniki, Greece, and received both his M.Sc. in Microbiology and Ph.D. in Molecular Biology from the University of Stockholm, Sweden. Dr. Xanthopoulos is a member of the board of directors of Anadys Pharmaceuticals, Odyssey Thera, Inc., and an executive board member of BIOCOM, Southern California's life science industry association, where he chairs the Capital Formation Committee.

PLENARY SESSION II: Keynote Address

Marcus Buckingham, Author, Independent Consultant and Speaker The Marcus Buckingham Company

Marcus Buckingham is considered one of the world's leading authorities on employee productivity and the practices of leading and managing. He jump-started the strengths revolution beginning with his best sellers First, Break All the Rules (coauthored with Curt Coffman, Simon & Schuster, 1999); Now, Discover Your Strengths (coauthored with Donald O. Clifton, The Free Press, 2001); The One Thing You Need to Know (The Free Press, 2005) and Go Put Your Strengths To Work (The Free Press, 2007). He provides important insights to maximizing strengths, understanding the crucial differences between leadership and management, and fulfilling the quest for long-lasting personal success. In his most recent book, Buckingham offers ways to apply your strengths for maximum success at work.

PLENARY SESSION III: Human Resources as a Strategic Business Partner: A CEO's Perspective

Gaylene Xanthopoulos, President of The Leadership Edge

Gaylene Xanthopoulos has a passion for helping people reach their potential. A successful businesswoman in her own right, Gaylene creates and presents custom training programs and keynote speeches that impart business skills to corporate leaders across the country. Gaylene is President of The Leadership Edge, a training and development organization she founded in 1989, to provide leadership, management, and business development programs to scientists, engineers and their executives. Through her nationally recognized program, From The Laboratory To Leadership, she and her team have successfully graduated over 3,000 scientific leaders from over 300 life science companies. Gaylene has served on the Board of Directors of the National Speakers Association, San Diego Chapter and has won numerous awards for her business and leadership successes including the San Diego Business Journal's Women Who Mean Business award. She is the author of numerous books, articles and programs including Tips, Techniques & Strategies On Referrals and A Women's Way to Incredible Success in Business. Gaylene holds a Bachelor of Science degree in Economics from the Wharton School of Business at the University of Pennsylvania, Philadelphia.

Dr. George Scangos, President and CEO, Exelixis, Inc.

George Scangos received a B.A. in Biology from Cornell University, a Ph.D. from the University of Massachusetts, and was a Jane Coffin Childs Postdoctoral Fellow in the laboratory of Dr. Frank Ruddle at Yale University. While in Dr. Ruddle's laboratory, Dr. Scangos, together with Dr. Jon Gordon, were the first to generate a transgenic mouse. Dr. Scangos then joined the faculty of The Johns Hopkins University, where he currently holds a position as Adjunct Professor. While at Johns Hopkins, Dr. Scangos' laboratory was one of the first to demonstrate that homologous recombination could occur in mammalian cells.

Dr. Scangos left Johns Hopkins in 1986 to work for Bayer Corporation, where he held several positions, including Senior Vice President of Research and Development for Bayer's pharmaceutical division, and then President of Bayer Biotechnology, where he lead an integrated group focused on discovery, development, and manufacture of biological products.

Dr. Scangos has served as President and Chief Executive Officer and Board Member of Exelixis since 1996. He currently serves as Chairman of Anadys Pharmaceuticals, and is on the Board of Entelos, Inc. Dr. Scangos is a member of the Board of Visitors of the University of California, San Francisco School of Pharmacy, the Board of Overseers of the University of California, Davis School of Medicine, and the Advisory Board for the Cornell University Life Sciences Initiative. Dr. Scangos also serves as a member of the Board of the Global Alliance for TB Drug Development.

Steven J. Mento, Ph.D., President, CEO, Co-founder, and Chairman of the Board of Conatus Pharmaceuticals Inc.

Dr. Mento is President, CEO, Co-founder, and Chairman of the Board of Conatus Pharmaceuticals Inc. He has held these positions since July of 2005. Dr. Mento has over twenty five years of combined experience in the biotechnology and pharmaceutical industry. From 1997 to 2005, Dr. Mento was President, Chief Executive Officer and a member of the Board of Directors of Idun Pharmaceuticals, Inc. Dr. Mento guided Idun during its transition from a discovery focused organization to a drug development company with multiple products in or near human clinical testing. In April 2005, Idun was sold to Pfizer.

Prior to joining Idun in 1997, Dr. Mento served as President of Chiron Viagene, Inc. Dr. Mento was a key member of the management team responsible for the sale of Viagene in 1995 to Chiron. Dr. Mento joined Viagene, a gene therapy company, in 1992 where he was Vice President of Research and Development. From 1982 to 1992, Dr. Mento held various positions of increasing responsibility at American Cyanamid Company. His final position was Director of Viral Vaccine Research and Development at Lederle-Praxis Biologicals, a business unit of American Cyanamid. From 1980 to 1982, Dr. Mento was Research Assistant Professor of Medicine and Microbiology at the Mount Sinai School of Medicine where he carried out research in animal models of virus-induced diabetes.

Dr. Mento holds Bachelor of Arts, Master of Science, and Ph.D. degrees in microbiology with an emphasis in virology from Rutgers University. He conducted post-doctoral research in somatic cell genetics at the University of Toronto.

Dr. Mento currently serves on the Boards of BIOCOM, BIO Emerging Company Section Governing Body, BIO Health Section Governing Body, Sangamo Biosciences, Inc., and selected academic and charitable organizations.

Bill Rastetter, CEO and Chairman, Apoptos, Chairman, Illumina, Partner, Venrock

Bill Rastetter joined Venrock in 2006 and comes to Venrock from Biogen Idec, where he was most recently executive chairman. Bill joined Idec Pharmaceuticals at its founding and grew it to a multi-billion-dollar market valuation company, while serving as CEO and chairman. Prior to Idec, he was Director of Corporate Ventures at Genentech, Inc. and also served in a scientific capacity at Genentech. Adding to his corporate background, Bill held various faculty positions including associate professor at MIT, won the award for "Excellence in the Teaching of Chemistry" at Harvard and is an Alfred P. Sloan Fellow. Bill is the author of numerous scientific papers and patent applications in the fields of organic and bio-organic chemistry, protein and enzyme engineering, and biotechnology; he is a co-inventor of Rituxan.

Bill currently serves on the board of Illumina as the company's chairman.

Quote from the website: "I've always focused on not only building companies, but also building sustainable corporate cultures that nurture the informed risk taking that drives growth, both for the corporation and for the individual entrepreneur. These cultures embrace change as a constant and see change as opportunity rather than threat. The corporation or the individual that always expects the world to be different tomorrow is better prepared to lead rather than follow trends and sea changes in their fields. This, I believe, is the key to successful entrepreneurship."

Education S.B., Chemistry, Massachusetts Institute of Technology, Phi Beta Kappa, Phi Lambda Upsilon
M.A., Chemistry, Harvard University
Ph.D., Chemistry, Harvard University

Steve Worland, Ph.D., President, Chief Executive Officer & Director, Anadys Pharmaceuticals

Steve Worland, Ph.D. was appointed President and Chief Executive Officer and a member of the Board of Directors on August 24, 2007. Dr. Worland joined Anadys as Chief Scientific Officer in 2001. In October 2004 he was promoted to Executive Vice President, Head of Research and Development, in December 2005. Dr. Worland was named Executive Vice President, Pharmaceuticals, and in June 2006 he was promoted to President, Pharmaceuticals. From 1999 to 2001 he was Vice President, Head of Antiviral Research, at Agouron Pharmaceuticals, a Pfizer Company. Dr. Worland was at Agouron from 1988 through the acquisition of Agouron by Warner-Lambert in 1999, where he held various positions and responsibilities that culminated with him assuming global responsibility for anti-infective strategy as Vice President for Warner-Lambert. At Agouron, Warner-Lambert and Pfizer, Dr. Worland led teams responsible for discovery and clinical development in the areas of HIV, HCV and Rhinovirus. Dr. Worland was a National Institutes of Health Postdoctoral Fellow in Molecular Biology at Harvard University from 1985 to 1988. He received his B.S. in Biological Chemistry from the University of Michigan and his Ph.D. in Chemistry from the University of California, Berkeley.